{
    "clinical_study": {
        "@rank": "127791", 
        "acronym": "MIDAS", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "BAY 86-5028; Levonorgestrel- Intra Uterine System"
        }, 
        "brief_summary": {
            "textblock": "The study is designed as non interventional to observe the continuation rate and the patient\n      satisfaction in women who have a  LNG-IUS (Levonorgestrel releasing Intrauterine system)\n      inserted for contraception over the period of 12 months under real life condition in\n      India.The study will begin after the study approval by ethics committee.All Indian women\n      aged between 18-49 years who are initiating LNG IUS therapy for contraception  will be\n      included in study after taking the informed consent.Patients will be observed for upto 12\n      months.The study involves general examination of patients, collection of data like medical\n      history, previous contraceptive use,concomitant medication etc.The study is planned to\n      enroll 600 subjects from multiple study centers spread across India. The study data will be\n      analyzed with appropriate statistical methods."
        }, 
        "brief_title": "MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Contraception", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject aged between 18-49 years who are initiating LNG IUS therapy for\n             contraception.\n\n          -  Subject willing to provide informed consent and comply with study procedure\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria must be read in conjunction with the local product information"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The study subjects will be enrolled from multiple sites like women's hospitals, tertiary\n        care institutes, Family planning clinics and gynaecological consulting centres"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961375", 
            "org_study_id": "16199", 
            "secondary_id": "MA1210IN"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion", 
            "intervention_name": "Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Levonorgestrel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "India"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_groups": "1", 
        "official_title": "MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage continuation rate of LNG IUS at end of observation period", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961375"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cumulative discontinuation rate for pregnancy", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Cumulative discontinuation rate for other medical reasons", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Cumulative discontinuation rate for non-medical reasons", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Mean percentage of women with amenorrhea", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Mean percent of women with spotting, inter-menstrual bleeding", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "contraceptive usage patterns included:birth-spacing, long term contraception, postpartum contraception, post-abortion contraception, switch from other method, contraception for other medical reasons like heart disease, etc", 
                "measure": "Distribution of contraceptive usage patterns", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Incidence rate of drug-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}